Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend
Strategic realignment to focus capital resources on clinical programs and reduce workforce by approximately 41%Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026Co-Founder and Board Director, Christopher Kirk, PhD, appointed...
Gitanjali Jain Christopher Kirk Noreen Roth Henig John Fowler Kezar Life Sciences Kezar Life Sciences Inc
Source: pharmiweb.com